Skip to main content
Equibles

Josh Smiley

CFO

ELI LILLY & Co (LLY)

COO

Zai Lab Ltd (ZLAB)

Equibles does not estimate personal net worth.

Get an email with a short summary when ELI LILLY & Co publishes a filing, an earnings call transcript or a press release.

Get LLY alerts

About Josh Smiley

Josh Smiley is recorded as CFO at ELI LILLY & Co (LLY) and COO at Zai Lab Ltd (ZLAB). The newest filing on record that lists Josh Smiley as COO at Zai Lab Ltd (ZLAB) is dated April 28, 2026. The proxy statement of Zai Lab Ltd reports total compensation of $5,550,550 for Josh Smiley in fiscal 2023, including a base salary of $637,500. Disclosed compensation is on record for 2 fiscal years. Josh Smiley has spoken on 18 earnings calls across 2 companies, most recently for Zai Lab Ltd on May 7, 2026. Those appearances were for Zai Lab Ltd (ZLAB) and ELI LILLY & Co (LLY). Zai Lab Ltd is classified in the Biotechnology industry within the Healthcare sector. ELI LILLY & Co is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Zai Lab Ltd includes Dr. Yajing Chen (CFO), Yajing Chen (CFO), John D. Diekman (Board Member) and 7 others.

Josh Smiley on recent calls

“I'll ask Rafael to take the first one, and then Yajin can take the second.”
COO, Q1 FY2026 Earnings conference call (announced in 8-K) ·
“I'll start with 2026, ask Yajing to make a comment, and then we'll hand it over to Rafael to talk about Zosie. I think as we think about 2026, as we mentioned on the upfront comments, we see good growth opportunities for VivGuard.”
COO, Q4 Earnings conference call (announced in 8-K) ·
“Let me start with VYVGART, where strong commercial execution continues to drive momentum in gMG. In the second quarter, we saw record levels of patient utilization, supported by a steady flow of new patient starts and increasing treatment duration.”
COO, Zai Lab Ltd Q2 FY2025 Earnings Call ·
“Following an exceptional 2024, we expect another strong year in 2025 with VYVGART sales growth expected to outpace total revenue growth, driven by increased patient demand, improved treatment continuity, and expanded access.”
COO, Zai Lab Ltd Q1 FY2025 Earnings Call ·
“We had a good year in 2024 as demonstrated by our strong commercial execution, important advancements across our regional and global R&D pipeline and multiple regulatory successes.”
COO, Zai Lab Ltd Q4 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Zai Lab Ltd

Leadership on record at ELI LILLY & Co

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2023 Zai Lab Ltd (ZLAB) $637,500 $5,550,550
2022 Zai Lab Ltd (ZLAB) $250,000 $8,296,517

Recent activity

Show 6 earlier activities